Perioperative Management of Patients who are Receiving a Novel Oral Anticoagulant (Dabigatran, Rivaroxaban or Apixaban) and Require an Elective Surgery or Medical Procedure: A Prospective Cohort Study (PAUSE)*
Completed
- Conditions
- Perioperative Use of Anticoagulantia for Surgery Evaluation1006447710043413
- Registration Number
- NL-OMON44377
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
- age > 18 years
- receiving a NOAC (dabigatran or rivaroxaban or apixaban) for stroke prevention for Atrial Fibrillation (SPAF)
- ability to adhere to the NOAC discontinuation protocol
- patient will be undergoing any elective surgical procedure or intervention
Exclusion Criteria
- CrCl <30 mL/min for dabigatran- and rivaroxaban-treated patients (<25 mL/min for apixaban-treated patients) as estimated by Cockroft-Gault formula
- Cognitive impairment or psychiatric illness that precludes collection of follow-up data
- Inability or unwillingness to provide informed consent
- Previous participation in this study having had a surgery/procedure performed
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method